[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"keloid-scars\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:keloid-scars":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100618803","phase-3-topical-cryotherapy-and-keloidhypertrophic-scars-100618803",false,"NCT07336368","Topical Cryotherapy and Keloid\u002FHypertrophic Scars","Topical Cryotherapy to Reduce Pain During Steroid Injections for Keloid and Hypertrophic Scars: A Pilot Study","Inclusion Criteria:\n\n* Adults (≥18 years) with keloids or hypertrophic scars already scheduled to receive intralesional triamcinolone (TAC) as part of routine care.\n* At least one keloid or hypertrophic scar with two comparable regions (≥2 cm each) suitable for split-treatment.\n* Able to provide informed consent and complete pain assessments in English.\n\nExclusion Criteria:\n\n* Keloid or hypertrophic scar located on the face (except earlobes), excluded for cosmetic reasons.\n* Prior treatment to the study-selected keloid\u002Fhypertrophic scar based on self-report.\n* Inability to complete study assessments due to cognitive or language barriers.","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The goal of this clinical trial is to determine whether the application of brief topical cryotherapy immediately before intralesional corticosteroid injections can reduce pain and injection resistance during routine treatment of keloid and hypertrophic scars in adult patients.\n\nThe main questions it aims to answer are:\n\nDoes topical cryotherapy applied before intralesional triamcinolone injection impact pain perceptions for participants with keloids or hypertrophic scars?\n\nDoes topical cryotherapy affect provider-assessed injection resistance compared with standard injection alone?\n\nResearchers will split the keloid\u002Fhypertrophic scar into two halves. One half will be treated with cryotherapy followed by steroid injection, while the other half will be treated with steroid injection alone to evaluate differences in pain perception and injection resistance.\n\nParticipants will rate pain after each injection using a 10-point numeric pain scale. Clinicians will rate the resistance after each injection using a 10-point numeric scale.",[26,27],"Keloid Scars","Hypertrophic Scars",[29,30,31,32,33,34,35],"Keloid scars","Hypertrophic scars","Cryotherapy","Intralesional corticosteroids","Pain reduction","Injection resistance","Injection pain","RECRUITING","2026-06-10",{"date":39,"type":40},"2026-06-12","ACTUAL",{"date":37,"type":40},{"date":43,"type":20},"2027-08",{"name":45,"class":46},"Sonal Choudhary","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100573834","phase-1-evaluation-of-clinical-perceived-and-instrumental-efficacy-of-a-scar-gel-in-preventing-hypertrophic-scars-100573834","NCT06751433","Evaluation of Clinical, Perceived and Instrumental Efficacy of a Scar Gel in Preventing Hypertrophic Scars","Evaluation of Clinical, Perceived and Instrumental Efficacy of a Scar Gel Versus Benchmark in Preventing Hypertrophic Scars and Improving Scar Appearance","Inclusion Criteria:\n\n1. Participants of both sexes aged between 18 and 70 years;\n2. Participants with recent scars (\\\u003C30 days);\n3. Participants with phototypes III to VI according to the Fitzpatrick scale;\n4. Agree to follow the trial procedures and attend the center on the days and times determined for evaluations;\n5. Understand, agree to and sign the free and informed consent form.\n6. Types of scars: cesarean section, breast implant or blunt cut injury.\n\nExclusion Criteria:\n\n1. Pregnancy or risk of pregnancy;\n2. History of atopic or allergic reactions to cosmetic products;\n3. Participants who are using topical antibiotics or other skin products on the same area being evaluated;\n4. Immunosuppression due to drugs or active diseases;\n5. Decompensated endocrine diseases;\n6. Relevant clinical history or current evidence of alcohol or other drug abuse;\n7. Known history or suspected intolerance to products in the same category;\n8. Intense sun exposure up to 15 days before the evaluation;\n9. Patients who are using topical antibiotics or other skin products on the same area being evaluated.","70 Years",{"count":57,"type":20},80,[59,60],"PHASE1","PHASE2","Evaluation of the safety and topical efficacy of a scar gel after 90 days of continuous use, comparing it to a benchmark for preventing hypertrophic scars and improving appearance, hydration and pigmentation.",[63,64,65,66,27,26],"Acceptability Study","Real-use Conditions","Safety and Efficacy","Topical Administration","2025-09-09",{"date":69,"type":40},"2025-09-11",{"date":71,"type":40},"2025-04-03",{"date":73,"type":20},"2025-12",{"name":75,"class":76},"Herbarium Laboratorio Botanico Ltda","INDUSTRY",2,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":21,"phases":89,"briefSummary":91,"conditions":92,"keywords":93,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":104,"leadSponsor":106,"locationsCount":47},"100585100","phase-4-comparison-of-intralesional-triamcinolone-versus-verapamil-for-keloid-treatment-100585100","NCT06897969","Comparison of Intralesional Triamcinolone Versus Verapamil for Keloid Treatment","Comparison of Intralesional Triamcinolone and Intralesional Verapamil in the Treatment of Keloids","Inclusion Criteria:\n\n* size of keloid1-5 cm,\n* on any site of the body,\n* duration less then five years and\n* baseline Vancouver scar score of more the or equal to 5\n\nExclusion Criteria:\n\n* Pregnant or lactating women,\n* family history of keloids,\n* acromegaly, and\n* congestive cardiac diseases","10 Years","50 Years",{"count":88,"type":20},60,[90],"PHASE4","This study aims to compare the efficacy of intralesional triamcinolone and verapamil in patients presenting with keloid at our local setting. The results will guide us towards better management of keloids by choosing the more appropriate treatment. Adequate treatment will reduce significant emotional and physical distress in patients. We hypothesized that mean reduction in Vancouver Scar Score is higher in triamcinolone acetonide group compared to verapamil after three months of treatment.",[26],[94,95,96,97,98],"Keloid","Vancouver scar scale","Triamcinolone","Verapamil","Intralesional injection","NOT_YET_RECRUITING","2025-03-26",{"date":102,"type":40},"2025-04-01",{"date":102,"type":20},{"date":105,"type":20},"2025-09-30",{"name":107,"class":46},"Nishtar Medical University"]